Literature DB >> 24363333

Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.

Julie Bruneau1, Geng Zang, Michal Abrahamowicz, Didier Jutras-Aswad, Mark Daniel, Elise Roy.   

Abstract

BACKGROUND: Notification of hepatitis C virus (HCV) positive status is known to have short-term impacts on subsequent alcohol, drug use and injection behaviors among persons who inject drugs (PWID). It remains to be established whether postscreening behavioral changes extend over time for PWID and whether screening test notification has behavioral impacts among HCV-negative PWID. This study sought to longitudinally assess substance use and injection behaviors after HCV status notification among HCV seroconverters and HCV-negative PWID.
METHODS: Initially HCV-seronegative PWID (n = 208) were followed prospectively between 2004 and 2011 in Montreal, Canada. Semiannual screening visits included blood sampling and an interview-administered questionnaire assessing substance use and injection behaviors. Multivariable generalized estimating equation analyses were conducted to assess substance use and behavior changes over time and compare changes between HCV seroconverters and HCV-seronegative participants while adjusting for baseline characteristics.
RESULTS: Of the 208 participants (83% male; mean age, 34.7 years, mean follow-up time, 39 months), 69 (33.2%) seroconverted to HCV. A linear decrease in syringe sharing behavior was observed over time after HCV and status notification, whereas a 10% decrease for each additional 3 months of follow-up was observed for injection cocaine and heroin use among HCV seroconverters but not among HCV-seronegative PWID (P < .05). No significant changes were observed in alcohol use.
CONCLUSIONS: Our results indicate that notification of HCV-positive status is associated with reduced injection drug use among seroconverters. Among PWID deemed seronegative after screening, there is no sustained trend for change in risk behavior.

Entities:  

Keywords:  behavior change; hepatitis C; injection drug use; screening

Mesh:

Year:  2013        PMID: 24363333     DOI: 10.1093/cid/cit938

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye?

Authors:  Curt G Beckwith; Sarah Larney; Timothy P Flanigan
Journal:  Clin Infect Dis       Date:  2013-12-20       Impact factor: 9.079

2.  A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs.

Authors:  T Spelman; M D Morris; G Zang; T Rice; K Page; L Maher; A Lloyd; J Grebely; G J Dore; A Y Kim; N H Shoukry; M Hellard; J Bruneau
Journal:  J Epidemiol Community Health       Date:  2015-03-26       Impact factor: 3.710

3.  Injection Partners, HCV, and HIV Status among Rural Persons Who Inject Drugs in Puerto Rico.

Authors:  Patrick Habecker; Roberto Abadie; Melissa Welch-Lazoritz; Juan Carlos Reyes; Bilal Khan; Kirk Dombrowski
Journal:  Subst Use Misuse       Date:  2017-11-22       Impact factor: 2.164

4.  Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.

Authors:  Andreea A Artenie; Nanor Minoyan; Brendan Jacka; Stine Høj; Didier Jutras-Aswad; Élise Roy; Lise Gauvin; Geng Zang; Julie Bruneau
Journal:  CMAJ       Date:  2019-04-29       Impact factor: 8.262

5.  Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic.

Authors:  Jamie P Morano; Alexei Zelenev; Andrea Lombard; Ruthanne Marcus; Britton A Gibson; Frederick L Altice
Journal:  J Community Health       Date:  2014-10

6.  Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Authors:  Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2015-07-17

7.  Correlates of perceived risk of HIV infection among persons who inject drugs in Tijuana, Baja California, Mexico.

Authors:  Richard F Armenta; Daniela Abramovitz; Remedios Lozada; Alicia Vera; Richard S Garfein; Carlos Magis-Rodríguez; Steffanie A Strathdee
Journal:  Salud Publica Mex       Date:  2015

Review 8.  HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia.

Authors:  Jonathan P Moorman; Matthew R Krolikowski; Stephanie M Mathis; Robert P Pack
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

9.  Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.

Authors:  Natasha K Martin; Peter Vickerman; Iain F Brew; Joan Williamson; Alec Miners; William L Irving; Sushma Saksena; Sharon J Hutchinson; Sema Mandal; Eamonn O'Moore; Matthew Hickman
Journal:  Hepatology       Date:  2016-03-22       Impact factor: 17.425

10.  Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study.

Authors:  Sabrina A Assoumou; Carlos R Sian; Christina M Gebel; Benjamin P Linas; Jeffrey H Samet; Judith A Bernstein
Journal:  Drug Alcohol Depend       Date:  2021-01-11       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.